Telix Pharmaceuticals Limited has submitted a marketing authorization application (MAA) in Europe for its glioma imaging candidate, TLX101-Px (O-(2-[18 F]fluoroethyl)-L-tyrosine, 18 F-FET). The announcement, made on February 18, 2026, marks a significant step in the company’s efforts to enhance diagnostic capabilities for brain cancer.
The submission comes as Telix concurrently prepares regulatory packages for both European and U.S. markets. By expediting the European filing to align with an agreed submission date, the company aims to broaden patient access to advanced brain imaging. This initiative supports current clinical practice guidelines and addresses a critical need for reliable imaging solutions in the diagnosis and management of gliomas.
In Europe, positron emission tomography (PET) imaging using 18 F-FET is currently available only under physician supervision at select hospital sites. There is no widely available commercial product, leading to inconsistent quality and limited access for glioma imaging. This gap presents a pressing need for Telix’s TLX101-Px, which promises to improve clarity in distinguishing progressive glioma from treatment-related changes, benefiting both adults and pediatric patients.
Philipp Lohmann, Group Leader at the Forschungszentrum Jülich research center in Germany, emphasized the importance of FET-PET imaging in clinical practice. He noted that it plays a critical role in treatment decision-making, especially in post-therapy scenarios where conventional MRI may not adequately differentiate between tumor progression and treatment effects. The availability of TLX101-Px could enhance clinicians’ ability to make informed decisions for patients with brain tumors.
Kevin Richardson, Chief Executive Officer of Telix Precision Medicine, described the submission as a pivotal milestone for the company. He stated, “We see a compelling opportunity in Europe to broaden access to authorized targeted radiopharmaceuticals for brain cancer imaging and therapy.” The strategic value of this application aligns with Telix’s development program for glioma treatment, which includes TLX101-Tx (iodofalan 131 I), currently undergoing a Phase 3 clinical trial known as IPAX-BrIGHT for recurrent glioblastoma.
Addressing the Unmet Need for Glioma Imaging
In Europe, approximately 67,500 brain and central nervous system tumors are diagnosed annually, with gliomas constituting around 30% of these cases and up to 80% of all malignant brain tumors. This highlights the critical unmet need for improved diagnosis and management of gliomas, particularly in the post-treatment setting. Conventional MRI imaging techniques often lack specificity and may produce inconclusive results, delaying essential treatment decisions.
Telix aims to address this challenge with TLX101-Px, which could provide greater biological insights into gliomas. The imaging candidate targets L-type amino acid transporters (LAT1 and LAT2) to enhance diagnostic accuracy. TLX101-Px is also being explored as a companion diagnostic for TLX101-Tx, reinforcing its potential role in both imaging and treatment paradigms.
As the submission progresses, Telix anticipates that regulatory approval will pave the way for TLX101-Px to be introduced in European markets under the proposed brand name “Pixlumi®.” The finalization of the brand name and commercial launch will depend on the outcomes of regulatory reviews.
About Telix Pharmaceuticals
Telix Pharmaceuticals is dedicated to developing and commercializing therapeutic and diagnostic radiopharmaceuticals aimed at addressing significant unmet medical needs in oncology and rare diseases. Headquartered in Melbourne, Australia, the company operates globally, including in the United States, United Kingdom, Brazil, Canada, Europe, and Japan. Telix is publicly traded on the Australian Securities Exchange (ASX: TLX) and the Nasdaq Global Select Market (NASDAQ: TLX).
For further information, including the latest updates and financial disclosures, visit Telix’s official website.
